Chemical and Toxicological Characterization of Arsenic Trioxide

Comprehensive Chemical and Toxicological Characterization of Arsenic Trioxide: A Specialized Analytical Service for Pharmaceutical Quality Assurance and Environmental Safety

Arsenic trioxide (As₂O₃) is a highly toxic compound that paradoxically serves as a critical active pharmaceutical ingredient (API) for the treatment of acute promyelocytic leukemia (APL), while also being a major environmental pollutant and an important industrial reagent. Its safety and efficacy are critically determined by absolute purity, speciation (As(III) vs. As(V)), the presence of heavy metal impurities, water content, solubility characteristics, and particle size distribution. Clients seeking testing for arsenic trioxide are typically motivated by the need to comply with pharmacopoeial monographs (USP, EP, JP) for injectable-grade drug substance, meet environmental discharge regulations, verify raw material quality for semiconductor applications, or troubleshoot unexpected toxicity or dissolution profiles. Our laboratory has established a fully validated, multi‑technique analytical platform that combines high‑precision titrimetry, advanced spectrometric speciation, crystal structure analysis, and dissolution profiling, delivering a definitive, risk‑based quality fingerprint that ensures your arsenic trioxide meets the most stringent regulatory and performance requirements.

Precise Assay and Speciation: Distinction Between As(III) and As(V)

The pharmacological activity and toxicological profile of arsenic trioxide depend on its oxidation state. We determine total arsenic by inductively coupled plasma optical emission spectrometry (ICP‑OES) and inductively coupled plasma tandem mass spectrometry (ICP‑MS/MS) after complete acid digestion, achieving relative expanded uncertainties (k=2) of < 0.5% for total As. Critically, we perform speciation analysis using high‑performance liquid chromatography coupled to ICP‑MS (HPLC‑ICP‑MS) with an anion‑exchange column to separate and quantify As(III) (arsenite) and As(V) (arsenate) with detection limits of 0.05 µg/L and reproducibility of < 1.5% RSD. For routine quality control, we also offer a validated selective reduction titrimetric method using iodine or potassium bromate under controlled pH to quantify the As(III) fraction, with precision of ±0.2% for typical purity levels. Our complete assay report provides the As₂O₃ equivalent purity, the fraction of As(III), and the total arsenic content, enabling you to verify conformity with pharmacopoeial limits (e.g., As(III) ≥ 99.5% for pharmaceutical grade).

Comprehensive Heavy Metal and Trace Element Impurity Profiling

Toxic impurities—particularly lead, cadmium, mercury, iron, and antimony—can significantly affect the safety and stability of arsenic trioxide products. We quantify over 40 trace elements using ICP‑MS/MS with collision/reaction cell technology (O₂, NH₃, H₂) to eliminate polyatomic interferences (e.g., ⁴⁰Ar³⁵Cl⁺ on ⁷⁵As, ⁴⁸Ca¹⁶O⁺ on ⁶⁴Zn). Detection limits are 0.01–0.5 ppb for most elements, with expanded uncertainties (k=2) < 5% relative at the limit of quantitation. We also perform mercury speciation by cold vapor atomic fluorescence spectrometry (CV‑AFS) after reduction, achieving detection limits of 0.001 ppb. All results are reported against the specified pharmacopoeial or regulatory limits (e.g., USP <231>, ICH Q3D), and we provide a clear pass/fail summary for elemental impurities.

Crystalline Phase Purity and Polymorphic Assessment by XRD

Arsenic trioxide exists in several crystalline polymorphs (cubic, monoclinic, and amorphous) that exhibit different dissolution rates and bioavailability. We perform high‑resolution powder X‑ray diffraction (HR‑XRD) with Cu Kα radiation over a 2θ range of 5–80° with a step size of 0.005°. Rietveld refinement determines the relative fractions of cubic (arsenolite) and monoclinic (claudetite) phases with an accuracy of ±0.5 wt%, and we report the crystallite size and microstrain. For amorphous content, we use internal standard addition (corundum) to quantify the amorphous fraction with a precision of ±1.5%. We also perform Raman microspectroscopy (with 532 nm and 785 nm lasers) to confirm the polymorphic identity via characteristic vibrational modes (e.g., As‑O stretching at 780 cm⁻¹) and to detect any surface hydration or carbonate contamination.

Dissolution Kinetics and Solubility Profiling

For pharmaceutical applications, the dissolution rate of arsenic trioxide directly influences the pharmacokinetic profile. We measure dissolution kinetics using a USP apparatus 2 (paddle) at 37 °C in various media (0.1 N HCl, pH 4.5 acetate buffer, pH 6.8 phosphate buffer, and purified water) with online UV‑Vis monitoring at 220 nm. We construct dissolution profiles and fit the data to Weibull, first‑order, and Higuchi models to extract dissolution rate constants and time to 80% release (T₈₀) with repeatability of < 2% RSD. We also determine the intrinsic dissolution rate (IDR) using a rotating disc apparatus in biorelevant media. For environmental and industrial samples, we measure water solubility by the shake‑flask method at 20 °C, 37 °C, and 60 °C, with ICP‑OES determination of total dissolved arsenic. These dissolution data are correlated with polymorphic composition to provide insights into batch‑to‑batch consistency.

Moisture, Volatile Impurities, and Loss on Drying

Moisture content and volatile impurities affect both stability and dosing accuracy. We determine loss on drying (LOD) by Thermogravimetric Analysis (TGA) from 30 °C to 200 °C under nitrogen, with precision of ±0.02%. For explicit water content, we employ coulometric Karl Fischer titration with a methanol‑based solvent and inert‑atmosphere sample handling, achieving detection limit of 10 ppm and reproducibility of < 2% relative. We also screen for volatile organic solvents (methanol, acetone, ethanol) by headspace GC‑MS with detection limits below 1 ppm, ensuring compliance with residual solvent guidelines (ICH Q3C).

Particle Size Distribution and Flowability for Dosage Form Development

For solid‑dosage formulations, the particle size distribution of arsenic trioxide directly affects content uniformity and dissolution. We measure particle size distribution (0.02–2000 µm) by laser diffraction in both dry (air dispersion) and wet (ethanol slurry) modes, reporting D10, D50, D90, and span with repeatability of < 1% RSD. We also determine specific surface area (BET) by nitrogen physisorption and bulk/tapped densities to calculate flowability indices (Hausner ratio, Carr index). These physical parameters are essential for process control in milling, blending, and tableting.

Environmental Stability and Leaching Behaviour

For industrial waste management and contaminated site assessment, we perform leaching tests according to TCLP (EPA Method 1311) and EN 12457, analysing the leachates by ICP‑MS for total arsenic and arsenic speciation. We also conduct accelerated stability studies under ICH conditions (25 °C/60% RH, 40 °C/75% RH, and accelerated photostability) for up to 6 months, with periodic re‑analysis of purity, speciation, and dissolution profiles. Our comprehensive stability report includes kinetic degradation constants and predicted shelf‑life under recommended storage conditions.

Our Distinctive Competencies and Analytical Superiority

Our service is uniquely distinguished by the orthogonal integration of HPLC‑ICP‑MS speciation, HR‑XRD polymorph quantification, dissolution profiling, ultra‑trace ICP‑MS/MS analysis, and stability testing—all performed on the same representative sample under stringent quality controls (ISO/IEC 17025 accreditation). We maintain in‑house reference materials (certified As₂O₃, arsenite, and arsenate standards) that are traceable to NIST SRMs and are routinely verified by interlaboratory comparisons.

Our proprietary data fusion algorithm combines over 25 parameters—including As(III) purity, heavy metal sum, polymorphic ratio, dissolution T₈₀, and moisture content—into a single “Arsenic Trioxide Quality Index” (ATQI™) that provides a quantitative, at‑a‑glance assessment of pharmaceutical or industrial fitness. This index has been validated against >30 commercial batches, enabling reliable supplier qualification and batch‑to‑batch trend analysis.

We achieve exceptional precision: < 0.2% RSD for As₂O₃ assay, < 0.5% RSD for As(III) speciation, < 1.0% RSD for dissolution rate constants, and < 0.1 m²/g for BET area. Our turnaround time for the full characterisation suite (including stability initiation) is 10–14 working days, with expedited 7‑day service for urgent batch release. Crucially, our team of PhD‑level analytical chemists, toxicologists, and pharmaceutical scientists provides a comprehensive interpretative report that translates each parameter into actionable insights—e.g., how an elevated As(V) fraction may indicate oxidation during storage, how particle size reduction can enhance bioavailability, or how trace iron contamination might accelerate the generation of reactive oxygen species. With over 20 successful projects on arsenic trioxide and related inorganic pharmaceutical compounds, we empower our clients to achieve regulatory compliance, ensure patient safety, and optimise their product quality with the highest level of scientific rigour and technical credibility.